[go: up one dir, main page]

AR133249A1 - NEW COMPOUNDS - Google Patents

NEW COMPOUNDS

Info

Publication number
AR133249A1
AR133249A1 ARP240101825A ARP240101825A AR133249A1 AR 133249 A1 AR133249 A1 AR 133249A1 AR P240101825 A ARP240101825 A AR P240101825A AR P240101825 A ARP240101825 A AR P240101825A AR 133249 A1 AR133249 A1 AR 133249A1
Authority
AR
Argentina
Prior art keywords
prevention
treatment
present
diseases
compounds
Prior art date
Application number
ARP240101825A
Other languages
Spanish (es)
Inventor
Sandro Boland
Egle Katkeviciute
Amuri Kilonda
Dominique Lambin
Arnaud Marchand
Vincent Pericolle
Kalliopi Pervolaraki
Michael Scharl
Marianne Spalinger
Jean Vanherck
- Versele Matthias Christophe
Original Assignee
Univ Leuven Kath
Univ Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leuven Kath, Univ Zuerich filed Critical Univ Leuven Kath
Publication of AR133249A1 publication Critical patent/AR133249A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a nuevos compuestos, a dichos compuestos para su uso como un medicamento, más específicamente para la prevención o tratamiento de enfermedades mediadas por la actividad de PTPN2 y/o PTPN1, aún más específicamente para la prevención o tratamiento del cáncer o enfermedades metabólicas. La presente invención además se refiere a un método para la prevención o tratamiento de dichas enfermedades que comprende el uso de los nuevos compuestos. La presente invención además se refiere a composiciones farmacéuticas o preparaciones combinadas de los nuevos compuestos, así como a dichas composiciones o preparaciones para su uso como un medicamento, con mayor preferencia para la prevención o tratamiento de enfermedades mediadas por la actividad de PTPN2 y/o PTPN1, aún más específicamente para la prevención o tratamiento del cáncer o enfermedades metabólicas. La presente invención además se refiere a procesos para la preparación de dichos compuestos. Un compuesto de la fórmula (1), una forma estereoisomérica, un tautómero, una sal (en particular una sal farmacéuticamente aceptable), un solvato, un hidrato, un polimorfo, un isótopo, y/o un profármaco del mismo.The present invention relates to novel compounds, to said compounds for use as a medicament, more specifically for the prevention or treatment of diseases mediated by PTPN2 and/or PTPN1 activity, even more specifically for the prevention or treatment of cancer or metabolic diseases. The present invention further relates to a method for the prevention or treatment of said diseases comprising the use of the novel compounds. The present invention further relates to pharmaceutical compositions or combined preparations of the novel compounds, as well as to said compositions or preparations for use as a medicament, more preferably for the prevention or treatment of diseases mediated by PTPN2 and/or PTPN1 activity, even more specifically for the prevention or treatment of cancer or metabolic diseases. The present invention further relates to processes for the preparation of said compounds. A compound of formula (1), a stereoisomeric form, a tautomer, a salt (in particular a pharmaceutically acceptable salt), a solvate, a hydrate, a polymorph, an isotope, and/or a prodrug thereof.

ARP240101825A 2023-07-14 2024-07-12 NEW COMPOUNDS AR133249A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP23185489 2023-07-14
EP24182972 2024-06-19

Publications (1)

Publication Number Publication Date
AR133249A1 true AR133249A1 (en) 2025-09-10

Family

ID=91856247

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP240101826A AR133250A1 (en) 2023-07-14 2024-07-12 NEW COMPOUNDS
ARP240101825A AR133249A1 (en) 2023-07-14 2024-07-12 NEW COMPOUNDS

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP240101826A AR133250A1 (en) 2023-07-14 2024-07-12 NEW COMPOUNDS

Country Status (3)

Country Link
AR (2) AR133250A1 (en)
TW (2) TW202519209A (en)
WO (2) WO2025016909A1 (en)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
UA94921C2 (en) * 2005-12-08 2011-06-25 Новартис Аг 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors
US20080293782A1 (en) * 2005-12-08 2008-11-27 David Barnes 1,1,3-Trioxo-1,2,5-Thiadiazolidines and Their Use as Ptp-Ases Inhibitors
PH12021552194A1 (en) 2019-03-14 2022-08-22 Abbvie Inc Protein tyrosine phosphatase inhibitors and methods of use thereof
EP4077291A1 (en) 2019-12-18 2022-10-26 Calico Life Sciences LLC Protein tyrosine phosphatase inhibitors and methods of use thereof
WO2021127586A1 (en) 2019-12-20 2021-06-24 Calico Life Sciences Llc Protein tyrosine phosphatase degraders and methods of use thereof
EP4305030A4 (en) 2021-03-11 2025-05-21 Kumquat Biosciences Inc. Heterocycles and uses thereof
IL313028A (en) 2021-11-23 2024-07-01 Kumquat Biosciences Inc Compounds containing heteroatoms and their uses
CN117658947A (en) * 2022-09-06 2024-03-08 杭州中美华东制药有限公司 5-(substituted aryl)-1,2,5-thiadiazolin-3-one compounds with protein tyrosine phosphatase inhibitory effects

Also Published As

Publication number Publication date
AR133250A1 (en) 2025-09-10
TW202519209A (en) 2025-05-16
WO2025016909A1 (en) 2025-01-23
TW202519514A (en) 2025-05-16
WO2025016906A1 (en) 2025-01-23

Similar Documents

Publication Publication Date Title
CO2022010460A2 (en) Substituted tricyclic compounds
CR20230616A (en) Triazolo-pyrimidine analogues for treating diseases connected to the inhibiton of werner syndrome recq helicase (wrn)
CL2022000271A1 (en) Pyrazolo(3,4-b)pyrazine shp2 phosphatase inhibitors.
BR112022003514A2 (en) Bifunctional brd9 degraders and their methods of use
CO2022008997A2 (en) Substituted tricyclic compounds
CL2023000921A1 (en) 1,2,3,4-tetrahydroquinoline derivatives as inhibitors of yap/taz-tead activation
UA109698C2 (en) AZAINDASOL OR DIAZAINDASOL DERIVATIVES AS A MEDICINE
MX2021011606A (en) Compounds targeting prmt5.
BRPI0607926A2 (en) spiro-oxindole compounds and their uses as therapeutic agents
PE20181778A1 (en) INDOLINE DERIVATIVES SUBSTITUTE AS INHIBITORS OF DENGUE VIRAL REPLICATION
MX2022003617A (en) HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OR IMPROVEMENT OF CANCER.
UY39799A (en) Pyrrolyl–sulfonamide compounds
MX2024002409A (en) CANCER THERAPIES.
CO2024015371A2 (en) Oxoindolinyl amide derivatives for inhibiting NLRP3 and their uses
CO2025003099A2 (en) Compounds for cancer treatment
AR128622A1 (en) MEK KINASE INHIBITORS
MX2022006333A (en) Tri-heterocyclic compound as jak inhibitor, and use thereof.
CO2022008616A2 (en) Oral pharmaceutical composition comprising carbamate compound and method of preparation therefor
DOP2019000299A (en) 5,6-FUSED BICYCLIC COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES
AR133249A1 (en) NEW COMPOUNDS
MX2022016497A (en) HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT, IMPROVEMENT OR PREVENTION OF FIBROTIC DISEASE.
MX2022009898A (en) Dihydronaphthyridinone compound, and preparation method therefor and medical use thereof.
AR128100A1 (en) COMPOUNDS FOR THE TREATMENT OF HAIR LOSS
CO2022004768A2 (en) Compounds and compositions for the treatment of parasitic diseases
UY39466A (en) COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CRYPTOSPORIDIOSIS